期刊
EXPERIMENTAL GERONTOLOGY
卷 128, 期 -, 页码 -出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.exger.2019.110743
关键词
Parkinson's disease; Schisandrol A; 6-OHDA; Neuroprotective; Motor symptoms; Nonmotor symptoms
资金
- National Natural Science Foundation of China [81573580]
- Key Laboratory of polysaccharide bioactivity evaluation of TCM of Liaoning Province
- Key techniques study of consistency evaluation of drug quality and therapeutic effect [18-400-4-08]
- Liaoning Distinguished Professor Project for Ying Jia (2017)
- Doctoral Scientific Research Foundation of Liaoning Province [2019-BS-233]
Parkinson's disease is the second most common neurodegenerative disease. Its main pathological feature is the substantial nigra-striatum dopaminergic neuronal dysfunction, which causes insufficient release of DA, induces motor symptoms, and is accompanied by nonmotor symptoms. Schisandrol A belongs to lignan components and has anti-inflammatory, antioxidant and neuroprotective effects. In this experiment, we injected 6-OHDA into medial forebrain bundle of C57BL/6J male mice to establish the model. The motor function of mice was examined by open field test and pole test, the depression-like behavior of mice was examined by sucrose preference test and the memory function was examined by Y maze. We found that schisandrol A (20 mg/kg/d) could significantly improve the motor symptoms, and alleviate the depression-like symptoms and memory dysfunction of PD mice induced by 6-OHDA. Then we studied the neuroprotective mechanism of schisandrol A by H.E., ELISA assay kits and Western blot. Results showed that schisandrol A may enhance the PI3K/AKT pathway, inhibit the IKK/I kappa B alpha/NF-kappa B pathway, reduce neuronal inflammation and oxidative stress, and enhance the survival of DA neurons in the brain of mice. These results indicate that schisandrol A is expected to be a potential drug for improving Parkinson's disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据